Log in

The Medicines Stock Price, Forecast & Analysis (NASDAQ:MDCO)

-1.92 (-3.64 %)
(As of 11/15/2019 06:18 AM ET)
Today's Range
Now: $50.89
50-Day Range
MA: $53.22
52-Week Range
Now: $50.89
Volume1.65 million shs
Average Volume1.58 million shs
Market Capitalization$4.06 billion
P/E RatioN/A
Dividend YieldN/A
The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MDCO



Sales & Book Value

Annual Sales$6.14 million
Book Value($0.75) per share


Net Income$-123,160,000.00


Market Cap$4.06 billion
Next Earnings Date2/26/2020 (Estimated)

Receive MDCO News and Ratings via Email

Sign-up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter.

The Medicines (NASDAQ:MDCO) Frequently Asked Questions

What is The Medicines' stock symbol?

The Medicines trades on the NASDAQ under the ticker symbol "MDCO."

How were The Medicines' earnings last quarter?

The Medicines Company (NASDAQ:MDCO) released its quarterly earnings data on Wednesday, October, 30th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by $0.12. During the same period in the previous year, the company earned ($0.70) earnings per share. View The Medicines' Earnings History.

When is The Medicines' next earnings date?

The Medicines is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for The Medicines.

What price target have analysts set for MDCO?

14 Wall Street analysts have issued 12-month price objectives for The Medicines' stock. Their forecasts range from $48.00 to $145.00. On average, they expect The Medicines' stock price to reach $73.33 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price. View Analyst Price Targets for The Medicines.

What is the consensus analysts' recommendation for The Medicines?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Medicines in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for The Medicines.

Has The Medicines been receiving favorable news coverage?

News coverage about MDCO stock has been trending somewhat negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. The Medicines earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for The Medicines.

Are investors shorting The Medicines?

The Medicines saw a increase in short interest in September. As of September 30th, there was short interest totalling 24,350,000 shares, an increase of 5.6% from the August 30th total of 23,050,000 shares. Based on an average daily trading volume, of 2,080,000 shares, the days-to-cover ratio is presently 11.7 days. Approximately 32.2% of the shares of the company are sold short. View The Medicines' Current Options Chain.

Who are some of The Medicines' key competitors?

What other stocks do shareholders of The Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other The Medicines investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), salesforce.com (CRM), Celgene (CELG), Intercept Pharmaceuticals (ICPT), Clovis Oncology (CLVS) and Vertex Pharmaceuticals (VRTX).

Who are The Medicines' key executives?

The Medicines' management team includes the folowing people:
  • Mr. Mark Timney, CEO & Director (Age 54)
  • Mr. Christopher J. Visioli, CFO & Treasurer (Age 43)
  • Mr. Stephen M. Rodin J.D., Exec. VP, Gen. Counsel & Sec. (Age 43)
  • Dr. Clive A. Meanwell, Chief Innovation Officer & Director (Age 61)
  • Dr. Goutham Krishna Gorti, VP & Head of Investor Relations

Who are The Medicines' major shareholders?

The Medicines' stock is owned by a number of of retail and institutional investors. Top institutional investors include Rhumbline Advisers (0.30%), Coronation Fund Managers Ltd. (0.21%), Alberta Investment Management Corp (0.20%), Rhenman & Partners Asset Management AB (0.19%), New York State Teachers Retirement System (0.19%) and California Public Employees Retirement System (0.17%). Company insiders that own The Medicines stock include Alexander J Denner, Armin M Kessler, Christopher T Cox, Clive Meanwell, Fredric N Eshelman, Mark Timney, Melvin K Spigelman, Stephen M Rodin and William Crouse. View Institutional Ownership Trends for The Medicines.

Which institutional investors are selling The Medicines stock?

MDCO stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Alberta Investment Management Corp, Creative Planning, Bailard Inc., Tokio Marine Asset Management Co. Ltd., Chicago Equity Partners LLC and First Mercantile Trust Co.. View Insider Buying and Selling for The Medicines.

Which institutional investors are buying The Medicines stock?

MDCO stock was bought by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, CIBC Private Wealth Group LLC, First Trust Advisors LP, Coronation Fund Managers Ltd., State of Alaska Department of Revenue, State of Tennessee Treasury Department, California Public Employees Retirement System and Russell Investments Group Ltd.. Company insiders that have bought The Medicines stock in the last two years include Alexander J Denner, Christopher T Cox, Fredric N Eshelman and Mark Timney. View Insider Buying and Selling for The Medicines.

How do I buy shares of The Medicines?

Shares of MDCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is The Medicines' stock price today?

One share of MDCO stock can currently be purchased for approximately $50.89.

How big of a company is The Medicines?

The Medicines has a market capitalization of $4.06 billion and generates $6.14 million in revenue each year. The company earns $-123,160,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. The Medicines employs 62 workers across the globe.View Additional Information About The Medicines.

What is The Medicines' official website?

The official website for The Medicines is http://www.themedicinescompany.com/.

How can I contact The Medicines?

The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected]

MarketBeat Community Rating for The Medicines (NASDAQ MDCO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  486 (Vote Outperform)
Underperform Votes:  351 (Vote Underperform)
Total Votes:  837
MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote "Outperform" if you believe MDCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDCO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel